Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections

被引:35
作者
Zhou, XJ
Gruber, W
Demmler, G
Jacobs, R
Reuman, P
Adler, S
Shelton, M
Pass, R
Britt, B
Trang, JM
Whitley, RJ
Sommadossi, JP
机构
[1] UNIV ALABAMA,DEPT PHARMACOL PEDIAT MICROBIOL & MED,DIV CLIN PHARMACOL,CTR AIDS RES,BIRMINGHAM,AL 35294
[2] UNIV ALABAMA,CTR COMPREHENS CANC,BIRMINGHAM,AL 35294
[3] VANDERBILT UNIV,NASHVILLE,TN 37232
[4] BAYLOR UNIV,WACO,TX 77030
[5] UNIV ARKANSAS,FAYETTEVILLE,AR 72702
[6] UNIV FLORIDA,GAINESVILLE,FL 32610
[7] VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,RICHMOND,VA 23298
[8] COOK FT WORTH CHILDRENS MED CTR,FT WORTH,TX 76104
关键词
D O I
10.1128/AAC.40.9.2202
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The population pharmacokinetics of ganciclovir was investigated in a group of 27 newborns with symptomatic congenital cytomegalovirus infection by nonlinear mixed effects modeling analysis. Individual characteristics including approximated creatinine clearance from serum (ASCC) and body weight (WGE) were identified to significantly influence total clearance from plasma (CL) and the apparent total volume of distribution (V) of ganciclovir, respectively. The regression equations used to model these relationships were expressed as CL (in liters per hour) = 0.262 + (0.00271 x ASCC) and V (in liters) = 0.627 + (0.437 x WGE). By using this model, typical values of the pharmacokinetic parameter CL and V were 0.428 +/- 0.079 liters/h and 1.773 +/- 0.320 liters, respectively. Upon validation with a larger number of newborns, this model should allow for the definition of possible relationships between the pharmacokinetic disposition of ganciclovir and pharmacodynamic events in neonates.
引用
收藏
页码:2202 / 2205
页数:4
相关论文
共 24 条
  • [1] BEAL SL, 1992, NONMEM USERS GUIDE
  • [2] BUHLES WC, 1988, REV INFECT DIS, V10, pS495
  • [3] DEITRICH DT, 1988, REV INFECT DIS, V10, pS532
  • [4] GANCICLOVIR - A REVIEW OF ITS ANTIVIRAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN CYTOMEGALOVIRUS INFECTIONS
    FAULDS, D
    HEEL, RC
    [J]. DRUGS, 1990, 39 (04) : 597 - 638
  • [5] 9-([2-HYDROXY-1-(HYDROXYMETHYL)ETHOXY]METHYL)GUANINE - A SELECTIVE INHIBITOR OF HERPES GROUP VIRUS-REPLICATION
    FIELD, AK
    DAVIES, ME
    DEWITT, C
    PERRY, HC
    LIOU, R
    GERMERSHAUSEN, J
    KARKAS, JD
    ASHTON, WT
    JOHNSTON, DBR
    TOLMAN, RL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (13): : 4139 - 4143
  • [6] HUMAN PHARMACOKINETICS OF THE ANTIVIRAL DRUG DHPG
    FLETCHER, C
    SAWCHUK, R
    CHINNOCK, B
    DEMIRANDA, P
    BALFOUR, HH
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (03) : 281 - 286
  • [7] LENGTH SERUM CREATININE RATIO DOES NOT PREDICT MEASURED CREATININE CLEARANCE IN CRITICALLY ILL CHILDREN
    FONG, J
    JOHNSTON, S
    VALENTINO, T
    NOTTERMAN, D
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (02) : 192 - 197
  • [8] GANCICLOVIR THERAPY OF SEVERE CYTOMEGALO-VIRUS INFECTIONS IN SOLID-ORGAN TRANSPLANT RECIPIENTS
    HARBISON, MA
    DEGIROLAMI, PC
    JENKINS, RL
    HAMMER, SM
    [J]. TRANSPLANTATION, 1988, 46 (01) : 82 - 88
  • [9] KEAY S, 1988, REV INFECT DIS, V10, pS563
  • [10] KWONG MBL, 1985, CLIN NEPHROL, V24, P285